MKSAP 19 Flashcards
6 most important lytic bone lesions?
Thyroid cancers.
Lymphoma (NHL)
Melanoma.
Multiple myeloma.
Renal cancer.
Sarcoidosis.
most important blastic bone lesion?
Prostate cancer
2 most important, lytic/blastic bone lesions?
Lung cancer.
Breast cancer.
Bone symptoms of Sjogren’s Syndrome
Non-erosive arthritis
Skin symptoms of Sjogren
Non-nodular rash
most common cause of kidney disease in patients with long-standing poorly controlled (not taking biologic therapy), inflammatory diseases, like ankylosing, spondylitis or rheumatoid arthritis?
AA amyloidosis-Renal amyloidosis, presenting as proteinuria
When to suspect AA amyloidosis in AS?
Men, pt with peripheral joint disease and with h/o uveitis
Urinalysis findings of Renal Amyloidosis vs Analgesic nephropathy
Isolated proteinuria vs pyuria/proteinuria and hematuria
2 main kidney diseases in AS (separate from secondary to NSAID use)
AA amyloidosis ( UA- isolated proteinuria), improves with aggressive AS treatment
IgA nephropathy ( UA- hematuria and proteinuria), unaffected by aggressive treatment of AS.
Interstitial nephritis clinical presentation?
Fever, rash, eosinophilia/eosinophiluria (not sensitive or specific).
Most common UA findings- Pyuria, WBC casts.
Other important findings- rise in creatinine, hematuria, proteinuria.
Which caution to exercise while prescribing Methotrexate in females?
Contraceptives should be given in females of child bearing age as Mtx is aw pregnancy loss and fetal abnormalities.
3 main TNFi
Abatacept, Tofacitinib and Rituximab
Mycophenolate mofetil moa
Reversible inhibitor is Inosine Monophosphate Dehydrogenase, affects lymphocyte stimulation and proliferation.
Prosthetic joint infections classification based on duration and most common causative agent?
Early onset (<3 months)- Staph Aureus
Delayed onset (3-12 months) - CONS (Staph epidermidis)
Late onset (>12 months)- Staph Aureus
Risk factors for Prosthetic joint infection with Pseudomonas Aeruginosa
H/o GI or GU infection or Immunosuppression.
Mainstay of treatment in SLE and why?
HCQ, reduces disease associated damage, prevent disease flares, and improve kidney and overall survival.
It also reduces risk of thrombosis, liver disease and MI and improve lipid profiles.
Classify SLE based on severity
Mild- no organ involvement.
Severe- organ involvement like nephritis, CNS disease.
Glucocorticoid indications and usage in SLE
Used in acute disease.
After disease stabilizes, taper to lowest effective dose, not more than 7.5 mg/d within 4-6 months, discontinue early if possible.
Azathioprine or MTX is recommended if patients with mild disease have refractory symptoms.
Important aspects of Management of SLE besides pharmacotherapy
Sun protection, vaccinations and LSM
Pharmacotherapy for severe SLE
Mycophenolate or cyclophosphamide, in addition to glucocorticoids and HCQ.
Bone and soft tissue changes in chronic gouty arthritis
soft tissue swelling, tophus, and well-defined erosions that have sclerotic borders and overhanging margins.
Considerations before pharmacotherapeutic management of an acute flare of gout
CKD (for Colchicine)
Bleeding risk / anticoagulation (Indomethacin)
Hyperglycemia (Prednisone)
Criteria for initiating Urate lowering therapy for patients with Gout
Gout with any of the following indications:
One or more subcutaneous tophi
Evidence of radiographic damage (any modality) attributable to gout
Frequent flares ( 2 or more annually)
Serum urate target with Urate Lowering Therapy
6